The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients-Reference-Cited by-同舟云学术

The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients

Published:2021-08-16 Issue:1 Volume:33 Page:e628-e634
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Montagna Emilia,Pagan Eleonora,Cancello Giuseppe,Sangalli Claudia,Bagnardi Vincenzo,Munzone Elisabetta,Salè Emanuela Omodeo,Malengo Daniela,Cazzaniga Marina Elena,Negri Mara,Peruzzotti Giulia,Veronesi Paolo,Viale Giuseppe,Colleoni Marco

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference20 articles.

1. Palbociclib and letrozole in advanced breast cancer.;Finn;N Engl J Med,2016

2. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.;Hortobagyi;Ann Oncol,2018

3. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer.;Goetz;J Clin Oncol,2017

4. Overall survival with palbociclib and fulvestrant in advanced breast cancer.;Turner;N Engl J Med,2018

5. Overall survival with ribociclib plus fulvestrant in advanced breast cancer.;Slamon;N Engl J Med,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and molecular characterization of the vinorelbine-platinum chemotherapeutic regimen in HER2(-) metastatic breast cancer;2024-06-20

2. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study;The Breast;2024-04

3. Low-grade serous ovarian cancer with BRAFV600E mutation treated with metronomic chemotherapy — a case report and literature review;Oncology in Clinical Practice;2023-09-08

4. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer;Thoracic Cancer;2023-07-04

5. Combination Treatment of Vinorelbine With Oral Cyclophosphamide or Capecitabine or Both Might Overcome Cross-resistance Against Eribulin in Advanced Breast Cancer;Clinical Breast Cancer;2022-10